STING1 and neoplasm: The therapeutic intratumoral administration of cGAMP (cyclic dinucleotide GMP-AMP) or CDNs (cyclic di-nucleotides) suppresses tumor growth, presumably through the direct activation of STING in the tumor microenvironment (TME), leading to the activation of phagocytic cells-dependent cytotoxic T lymphocytes response20–22.